PRODUCT MONOGRAPH

PRIMAXIN®

(imipenem and cilastatin sodium for injection, USP)

I.V. Infusion

ANTIBIOTIC

MERCK FROSST CANADA LTD.
Kirkland, Quebec, Canada

Control: 118199

Date of Revision:
February 18, 2008

NAME OF DRUG

PRIMAXIN®

(imipenem and cilastatin sodium for injection, USP)

I.V. Infusion

THERAPEUTIC CLASSIFICATION

Antibiotic

ACTION

Imipenem exerts a bactericidal action by inhibiting cell wall synthesis in aerobic and anaerobic gram-positive and gram-negative bacteria.

PRIMAXIN® (imipenem and cilastatin sodium) consists of two components: (1) imipenem, a derivative of thienamycin, a carbapenem antibiotic; and (2) cilastatin sodium, a specific inhibitor of dehydropeptidase-I a renal enzyme which metabolizes and inactivates imipenem. Cilastatin blocks the metabolism of imipenem in the kidney, so that concomitant administration of imipenem and cilastatin allows antibacterial levels of imipenem to be attained in the urine.

Inhibition of cell-wall synthesis is achieved in gram-negative bacteria by the binding of imipenem to penicillin binding proteins (PBPs). In the case of *Escherichia coli* and selected strains of *Pseudomonas aeruginosa*, imipenem has been shown to have highest affinity for PBP-2, PBP-1a and PBP-1b, with lower activity against PBP-3. The preferential binding of imipenem on PBP-2 and PBP-1b leads to direct conversion of the individual cell to a spheroplast resulting in rapid lysis and cell death without filament formation. When imipenem is removed prior to complete killing of gram-negative species, the remaining viable cells show a measurable lag, termed a "post-antibiotic effect" (PAE), prior to resumption of new growth.

INDICATIONS AND CLINICAL USE

PRIMAXIN® (imipenem and cilastatin sodium) may be indicated in the treatment of serious infections when caused by sensitive strains of bacteria. Where considered necessary, therapy may be initiated on the basis of clinical judgment before results of sensitivity testings are available. Continuation of therapy should be reevaluated on the basis of bacteriological findings and of the patient's clinical condition.

Imipenem is active *in vitro* against a wide range of gram-positive and gram-negative aerobic and anaerobic bacteria, including most strains which are beta-lactamase producing. Patients have responded while under treatment with PRIMAXIN® for single or mixed infections of the following body systems, when they were associated with a number of pathogenic species and strains of the genera listed:

1. Lower Respiratory Tract Infections
2. Urinary Tract Infections
3. Intra-Abdominal Infections
4. Gynecological Infections
5. Septicemia
6. Endocarditis caused by *Staphylococcus aureus*
7. Bone and Joint Infections
8. Skin Structure Infections

PRIMAXIN® is not indicated for the treatment of meningitis.

Gram-positive Aerobes

Listeria monocytogenes
Nocardia asteroides
Staphylococcus (excluding many strains which are methicillin resistant)
Streptococcus (excluding *S. faecium*)

Gram-negative Aerobes

Acinetobacter
Citrobacter
Enterobacter
Escherichia coli
Haemophilus influenzae
Haemophilus parainfluenzae
Klebsiella
Morganella morganii
Neisseria
Proteus (indole positive and indole negative strains)
Providencia
Pseudomonas aeruginosa
Serratia marcescens

Gram-positive Anaerobes

Clostridium (excluding *C. difficile*)
Peptococcus
Peptostreptoccus

Gram-negative Anaerobes

Bacteroides fragilis
Bacteroides (non fragilis)

CONTRAINDICATIONS

PRIMAXIN® (imipenem and cilastatin sodium) is contraindicated in patients who have shown hypersensitivity to either component of this product.

WARNINGS

PRIMAXIN® (imipenem and cilastatin sodium) SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF ALLERGY, PARTICULARLY TO STRUCTURALLY-RELATED DRUGS. IF AN ALLERGIC REACTION TO PRIMAXIN® OCCURS,

DISCONTINUE THE DRUG. SERIOUS HYPERSENSITIVITY REACTIONS MAY REQUIRE EPINEPHRINE AND OTHER EMERGENCY MEASURES.

Pseudomembranous colitis

Pseudomembranous colitis has been reported with the use of PRIMAXIN®. Therefore it is important to consider this diagnosis in patients who develop diarrhea during or after therapy. This colitis may range from mild to life threatening in severity.

Mild cases of pseudomembranous colitis may respond to drug discontinuance alone. In more severe cases, management may include sigmoidoscopy, appropriate bacteriological studies, fluid, electrolyte and protein supplementation, and the use of a drug such as oral vancomycin, as indicated. Other causes of colitis should also be considered.

PRECAUTIONS

General

Prolonged use of PRIMAXIN® (imipenem and cilastatin sodium) may result in overgrowth of resistant organisms. Repeated evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken.

CNS adverse experiences such as myoclonic activity, confusional states, or seizures have been reported with PRIMAXIN® especially when recommended dosages based on renal function and body weight were exceeded. These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) and/or who have compromised renal function. However, there were rare reports in which there was no recognized or documented underlying CNS disorder. Close adherence to recommended dosage schedules is urged especially in patients with known factors that predispose to seizures (see DOSAGE AND ADMINISTRATION).

Anticonvulsant therapy should be continued in patients with a known seizure disorder. If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically and placed on anticonvulsant therapy if not already instituted. If CNS symptoms continue, the dosage of PRIMAXIN® should be decreased or discontinued (see Drug-Drug Interactions).

Use in Patients with Impaired Renal Function

Dosage in patients with impaired renal function is based on the severity of infection but the maximum daily dose varies with the degree of renal functional impairment (see DOSAGE AND ADMINISTRATION - Dosage in Patients with Renal Insufficiency).

Use in Pregnancy

The use of PRIMAXIN® in pregnant women has not been studied, therefore, PRIMAXIN® should be used during pregnancy only if clearly needed. Use of this drug in women of childbearing potential requires that the anticipated benefits be weighed against possible hazards.

Reproduction studies with bolus I.V. doses suggest an apparent intolerance to PRIMAXIN® (including emesis, inappetence, body weight loss, diarrhea and death) at doses equivalent to the average human dose in pregnant rabbits and cynomolgus monkeys that is not seen in non-pregnant animals in these or other species. In other studies, PRIMAXIN® was well tolerated in equivalent or higher doses (up to 11 times the average human dose) in pregnant rats and mice (see REPRODUCTION STUDIES under TOXICOLOGY).

Nursing Mothers

Imipenem has been detected in human milk. If the use of PRIMAXIN® is deemed essential, the patient should stop nursing.

Pediatric Use

Efficacy and tolerability in infants under the age of 3 months have not yet been established; therefore, PRIMAXIN® is not recommended in the pediatric age group below the age of 3 months.

Drug Interactions

Drug-Drug Interactions

Generalized seizures have been reported in patients who received ganciclovir and PRIMAXIN®. These drugs should not be used concomitantly unless the potential benefits outweigh the risks.

Decreased serum levels of valproic acid with co-administration of carbapenem antibiotics, including imipenem, have been reported during post-marketing and in some cases breakthrough seizures have occurred. Careful monitoring of serum levels of valproic acid should be considered if imipenem to be co-administered with valproic acid.

Concomitant administration of PRIMAXIN® and probenecid results in only minimal increases in plasma levels of imipenem and plasma half-life. It is not recommended that probenecid be given with PRIMAXIN®.

PRIMAXIN® should not be mixed with or physically added to other antibiotics. PRIMAXIN® has been administered concomitantly with some antibiotics, such as aminoglycosides.

There is no evidence to suggest that association of PRIMAXIN® with any other beta-lactam antibiotics has any therapeutic advantage.

ADVERSE REACTIONS

PRIMAXIN® (imipenem and cilastatin sodium) is generally well tolerated. The following adverse reactions were reported on 1,723 patients treated in clinical

trials. Many of these patients were severely ill and had multiple background diseases and physiological impairments, making it difficult to determine causal relationship of adverse experiences to therapy with PRIMAXIN®.

Local Adverse Reactions

Adverse local clinical reactions that were reported as possibly, probably or definitely related to therapy with PRIMAXIN® were:

	Incidence (%)
Phlebitis/thrombophlebitis	1.7
Infused vein pain	0.6
Vein induration	0.2
Infused vein infection	0.1

Systemic Adverse Reactions

Adverse clinical reactions that were reported as possibly, probably or definitely related to PRIMAXIN® were:

	Incidence (%)
Gastrointestinal	
nausea	2.0
diarrhea	1.7
vomiting	1.6
tongue papillar hypertrophy	0.2
pseudomembranous colitis (see WARNINGS)	0.1
hemorrhagic colitis	<0.1
gastroenteritis	<0.1
abdominal pain	<0.1
glossitis	<0.1
heartburn	<0.1
pharyngeal pain	<0.1
increased salivation	<0.1

	Incidence (%)
	Incidence (%)
CNS	
fever	0.4
dizziness	0.3
seizures (see PRECAUTIONS)	0.2
somnolence	0.2
confusion	0.2
myoclonus	0.1
vertigo	0.1
headache	0.1
encephalopathy	<0.1
paresthesia	<0.1
Special Senses	
transient hearing loss in patients with impaired hearing	<0.1
tinnitus	<0.1
Respiratory	
dyspnea	0.1
hyperventilation	<0.1
thoracic spine pain	<0.1
	Incidence (%)
Cardiovascular	
hypotension	0.4
palpitations	0.1
tachycardia	<0.1
Renal	
oliguria/anuria	<0.1
polyuria	<0.1
Skin	
rash	0.9
pruritus	0.3
urticaria	0.2
skin texture changes	0.1
candidiasis	0.1
erythema multiforme	<0.1
facial edema	<0.1

	Incidence (%)
flushing	<0.1
cyanosis	<0.1
hyperhidrosis	<0.1
pruritus vulvae	<0.1
Body as a whole	
polyarthralgia	<0.1
asthenia/weakness	<0.1

Adverse Laboratory Changes

Adverse laboratory changes, without regard to drug relationship, that were reported during clinical trials were:

Hepatic: Increased SGPT, SGOT, alkaline phosphatase, bilirubin and LDH.

Hemic: Increased eosinophils, positive Coombs' test, decreased WBC and neutrophils, increased WBC, increased platelets, decreased platelets, decreased hemoglobin and hematocrit, increased monocytes, abnormal prothrombin time, increased lymphocytes, increased basophils.

Electrolytes: Decreased serum sodium, increased potassium, increased chloride.

Renal: Increased BUN, creatinine.

Urinalysis: Presence of urine protein, urine red blood cells, urine white blood cells, urine casts, urine bilirubin, and urine urobilinogen.

Post-Market Adverse Drug Reactions

The following reactions have been reported since the drug was marketed, but occurred under circumstances where a causal relationship could not be established. However, in these rarely reported events, that possibility cannot be excluded. Therefore, these observations are listed to serve as alerting information to physicians and pharmacists:

- Acute renal failure. The role of PRIMAXIN® in changes in renal function is difficult to assess, since factors predisposing to pre-renal azotemia or to impaired renal function usually have been present.
- Anaphylactic reactions
- Bone marrow depression
- Exfoliative dermatitis
- Hallucinations
- Hearing loss
- Hemolytic anemia
- Hepatic failure
- Hepatitis
- Fulminant hepatitis
- Pancytopenia
- Psychic disturbances
- Staining of teeth
- Stevens-Johnson syndrome
- Taste perversion
- Toxic epidermal necrolysis
- Urine discoloration.

OVERDOSAGE

There are no data available on overdosage. PRIMAXIN® (imipenem and cilastatin sodium) is cleared by hemodialysis.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

DOSAGE AND ADMINISTRATION

The dosage recommendations for PRIMAXIN® (imipenem and cilastatin sodium) represent the quantity of imipenem to be administered by I.V. infusion only. An equivalent amount of cilastatin is also present in the solution.

The dosage of PRIMAXIN® should be determined by the severity of the infection, renal function, body weight, the antibiotic susceptibility of the causative organism(s) and the condition of the patient. Doses cited are based on body weight of 70 kilos.

The median duration of treatment with PRIMAXIN® in clinical trials for infections of the various body systems ranged from 6 to 10 days except for endocarditis and bone and joint infections for which the median duration of treatment was 4 weeks.

Dosage in Adults

The recommended daily dose is 1 to 2 g administered in equally divided doses every 6 to 8 hours (see Table 1).

TABLE 1
ADULT DOSAGE OF PRIMAXIN®

	I.V. Administration		
Severity of infection	**Dose (mg of imipenem)**	**Dosage Interval**	**Daily Dose**
Mild	250 mg	6 h	1.0 g
Moderate	500 mg	8 h	1.5 g
Severe (fully susceptible)	500 mg	6 h	2.0 g
Severe* infections due to less susceptible organisms or life threatening conditions	1000 mg 1000 mg	8 h 6 h	3.0 g 4.0 g

* Primarily some strains of *P. aeruginosa*.

The maximum daily dose should not exceed 4 g or 50 mg/kg, whichever is less.

Dosage in Elderly Patients

The recommended dosage of PRIMAXIN® in elderly patients with normal renal function is the same as given for adults above. Renal status of elderly patients may not be accurately portrayed by measurement of BUN or creatinine alone. Determination of creatinine clearance is suggested to provide guidance for dosing in such patients.

Dosage in Patients with Renal Insufficiency

Patients with creatinine clearances of ≤ 5 mL/min/1.73 m^2 (≤ 0.08 mL/s/1.73 m^2) should not receive PRIMAXIN® unless hemodialysis is instituted within 48 hours. Both imipenem and cilastatin are cleared from the circulation during hemodialysis. The patient should receive PRIMAXIN® after hemodialysis and at 12 hour intervals timed from the end of that hemodialysis session. Dialysis patients, especially those with background CNS disease, should be carefully monitored; for patients on hemodialysis, PRIMAXIN® is recommended only when the benefit outweighs the potential risk of seizures (see PRECAUTIONS). Currently, there are inadequate data to recommend the use of PRIMAXIN® in patients undergoing peritoneal dialysis.

TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN® IN RELATION TO RENAL FUNCTION

RENAL FUNCTION	CREATININE CLEARANCE mL/min/1.73 m^2 (mL/s/1.73 m^2)	MAXIMUM TOTAL DAILY DOSAGE for infections due to fully susceptible organisms	MAXIMUM TOTAL DAILY DOSAGE for infections due to less susceptible organisms**
Mild impairment	31 - 70 (0.52 - 1.17)	1.5 g (0.5 g q8h)	2.0 g (0.5 g q6h)
Moderate impairment	21 - 30 (0.35 - 0.50)	1.0 g (0.5 g q12h)	1.5 g (0.5 g q8h)
Severe impairment*	0 - 20 (0 - 0.33)	0.5 g (0.25 g q12h)	1.0 g (0.5 g q12h)

* Patients with creatinine clearance of 6 to 20 mL/min/1.73 m^2 (0.1 - 0.3 mL/s/1.73 m^2) should be treated with 250 mg (or 3.5 mg/kg whichever is lower) every 12 hours for most pathogens. When the 500 mg dose is used in these patients, there may be an increased risk of seizures.

** Primarily some strains of *P. aeruginosa.*

A further proportionate reduction in dose administered must be made for patients with a body weight <70kg.

When only the serum creatinine level is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance (mL/min). The serum creatinine should represent a steady state of renal function.

Males: $\frac{\text{Weight (kg) x (140 - age)}}{\text{72 x serum creatinine (mg/100 mL)}}$

Females: 0.85 x above value.

When using the International System of units (SI), the estimated creatinine clearance (mL/s) in males can be calculated as follows:

$$\frac{\text{(lean body weight, kg) x (140 - age, years) x 1.4736}}{\text{(72) x (serum creatinine concentration, µmol/L)}}$$

and in females, the estimated creatinine clearance (mL/s) is:

$$\frac{\text{(lean body weight, kg) x (140 - age, years) x 1.2526}}{\text{(72) x (serum creatinine concentration, µmol/L)}}$$

PRIMAXIN® is cleared by hemodialysis. After each dialysis session the dosage schedule should be restarted.

Dosage in Infants and Children

The recommended total daily dosage of PRIMAXIN® in children and infants 3 months of age and older is 60 to 100 mg/kg of body weight divided into 4 equal doses given at six hour intervals. The higher dosages should be used for infants and young children. The total daily dosage should not exceed 2 grams. Clinical data are insufficient to recommend an optimum dose for infants and children with impaired renal function.

PRIMAXIN® is not recommended for the therapy of meningitis. If meningitis is suspected, an appropriate antibiotic should be used.

PRIMAXIN® may be used in children with sepsis as long as they are not suspected of having meningitis.

Administration

CAUTION: CONTENTS OF VIALS NOT FOR DIRECT INFUSION.

Each reconstituted 250 mg or 500 mg dose should be given by intravenous infusion over twenty to thirty minutes. Each 1000 mg dose should be infused over 40 to 60 minutes. In patients who develop nausea during the infusion, the rate of infusion may be slowed (for reconstitution, see RECONSTITUTION under PHARMACEUTICAL INFORMATION).

PHARMACEUTICAL INFORMATION

CHEMISTRY

Proper name: imipenem and cilastatin sodium for injection

Chemical names:

Imipenem

(5*R*,6*S*)-3-[[2-(formimidoylamino)ethyl] thio]-6-[(*R*)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate.

Cilastatin sodium

Sodium (*Z*)-7-[[(*R*)-2-amino-2-carboxyethyl]thio]-2-[(*S*)-2,2-dimethylcyclopropane-carboxamido]-2-heptenoate.

Structural Formulae:





Molecular formulae:

$C_{12}H_{17}N_3O_4S \cdot H_2O$

$C_{16}H_{25}N_2O_5S\ Na$

Molecular Weights:

317.37

380.43

Descriptions:

Imipenem is an off-white, nonhygroscopic crystalline compound. It is sparingly soluble in water, and slightly soluble in methanol.

Cilastatin is an off-white to yellowish-white, hygroscopic, amorphous compound. It is very soluble in water and in methanol.

Composition:

Imipenem and cilastatin sodium are present in PRIMAXIN® in a 1:1 ratio by weight with sodium bicarbonate as a buffer.

Reconstitution

PRIMAXIN® is supplied either in vials or in ADD-Vantage* vials of either 250 mg or 500 mg imipenem equivalent and cilastatin equivalent when reconstituted.

a) Vials - PRIMAXIN®

Contents of the vials must be suspended and transferred to 100 mL of an appropriate infusion solution.

A suggested procedure is to transfer approximately 10 mL from the 100 mL of the appropriate infusion solution to the vial (see list of diluents under **COMPATIBILITY AND STABILITY**). Shake well. Return the resulting 10 mL of suspension to the remaining 90 mL of the infusion solution.

Repeat, using 10 mL of the diluted suspension, to ensure complete transfer of the contents of the vial to the infusion solution.

CAUTION: CONTENTS OF VIALS NOT FOR DIRECT INFUSION.

b) ADD-Vantage* Vials - PRIMAXIN®

When administering PRIMAXIN® using the ADD-Vantage* drug delivery system, PRIMAXIN® sterile powder is added directly to a single-dose flexible plastic ADD-Vantage* diluent container.

---

* Registered trademark of Abbott Laboratories

SOLUTIONS FOR RECONSTITUTION

Use Abbott Laboratories' ADD-Vantage* diluent containers containing 100 mL or 250 mL of either:

5% Dextrose Injection or
0.9% Sodium Chloride Injection

Reconstitute as follows:

RECONSTITUTION TABLE

STRENGTH	AMOUNT OF DILUENT TO BE ADDED (mL)+	APPROXIMATE WITHDRAWABLE VOLUME (mL)	APPROXIMATE AVERAGE CONCENTRATION (mg/mL)
250/250	100 or 250	100 or 250	2.5 or 1.0
500/500	100 or 250	100 or 250	5.0 or 2.0

+ Shake to dissolve and let stand until clear.

See **SPECIAL INSTRUCTIONS** (ADD-Vantage*)

SPECIAL INSTRUCTIONS (ADD-Vantage*)

To Open Diluent Container:

Peel overwrap from the corner and remove container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

* Registered trademark of Abbott Laboratories

To Assemble Vial and Flexible Diluent Container:

(Use Aseptic Technique)

1. Remove the protective covers from the top of the vial and the vial port on the diluent container as follows:

   a) To remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening (see FIGURE 1). Pull the ring approximately half way around the cap and then pull straight up to remove the cap (see FIGURE 2).

Fig. 1

Fig. 2

   b) To remove the vial port cover, grasp the tab on the pull ring, pull up to break the three tie strings, then pull back to remove the cover (see FIGURE 3).

2. Screw the vial into the vial port until it will go no further. THE VIAL MUST BE SCREWED IN TIGHTLY TO ASSURE A SEAL. This occurs approximately ½ turn (180^{o}) after the first audible click (see FIGURE 4). The clicking sound does not assure a seal; the vial must be turned as far as it will go. **NOTE:** Once vial is seated, do not attempt to remove (see FIGURE 4).

Fig. 3



Fig. 4

3. Recheck the vial to assure that it is tight by trying to turn it further in the direction of assembly.

4. Label appropriately.

To Prepare Admixture:

1. Squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial.

2. With the other hand, push the drug vial down into the container telescoping the walls of the container. Grasp the inner cap of the vial through the walls of the container (see FIGURE 5).

3. Pull the inner cap from the drug vial (see FIGURE 6). Verify that the rubber stopper has been pulled out, allowing the drug and diluent to mix.

4. Mix container contents thoroughly and use within the specified time.



Fig. 5 Fig. 6

Preparation for Administration

(Use Aseptic Technique)

1. Confirm the activation and admixture of vial contents.
2. Check for leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired.
3. Close flow control clamp of administration set.
4. Remove cover from outlet port at bottom of container.

5. Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated. **NOTE:** See full directions on administration set carton.
6. Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings. Bend the loop outward to lock it in the upright position, then suspend container from hanger.
7. Squeeze and release drip chamber to establish proper fluid level in chamber.
8. Open flow control clamp and clear air from set. Close clamp.
9. Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.
10. Regulate rate of administration with flow control clamp.

WARNING: Do not use flexible containers in series connections.

COMPATIBILITY AND STABILITY

List of diluents

- 0.9% Sodium Chloride Injection
- 5% or 10% Dextrose Injection
- 5% Dextrose Injection with 0.02% sodium bicarbonate solution
- 5% Dextrose with 0.9% Sodium Chloride Injection
- 5% Dextrose with 0.225% or 0.45% saline solution
- 5% Dextrose with 0.15% potassium chloride solution
- Mannitol 5% and 10%

Reconstituted solutions

Solutions of PRIMAXIN® range from colourless to yellow. Variations of colour within this range do not affect the potency of the product.

PRIMAXIN®, as supplied in vials and reconstituted as above maintains satisfactory potency for **four hours at room temperature and for 24 hours under refrigeration (4°C)**.

PRIMAXIN®, as supplied in ADD-Vantage vials and reconstituted with either 0.9% sodium chloride injection of 5% Dextrose, injection, maintains satisfactory potency for four hours at room temperature.

AVAILABILITY OF DOSAGE FORMS

PRIMAXIN® (imipenem and cilastatin sodium) is supplied as a sterile powder mixture in vials containing imipenem anhydrous and cilastatin sodium with sodium bicarbonate as a buffer as follows:

250 mg imipenem equivalent and 250 mg cilastatin equivalent in vials.

500 mg imipenem equivalent and 500 mg cilastatin equivalent in vials.

250 mg imipenem equivalent and 250 mg cilastatin equivalent in ADD-Vantage* vials.

500 mg imipenem equivalent and 500 mg cilastatin equivalent in ADD-Vantage* vials.

STORAGE

The dry powder should be stored at 15°C-30°C.

* Registered trademark of Abbott Laboratories

MICROBIOLOGY

The *in vitro* activity of imipenem against clinical isolates of various gram-positive and gram-negative aerobic and anaerobic species is shown in Table 3. Published studies were compiled to show the mean MIC_{50}s, MIC_{90}s and upper range as well as the distribution of these statistics among the many studies. The distribution is calculated as a frequency weighted cumulative distribution showing the minimum percent of isolates susceptible at the indicated concentrations.

Imipenem has antimicrobial activity against a range of clinically significant gram-positive and gram-negative aerobic and anaerobic pathogens. Imipenem exerts a bactericidal effect over a broad range of species at concentrations equal or close to the MIC (Table 3).

TABLE 3

THE *IN VITRO* ACTIVITY OF IMIPENEM AGAINST CLINICAL ISOLATES OF VARIOUS GRAM-POSITIVE AND GRAM-NEGATIVE AEROBIC AND ANAEROBIC SPECIES

Organism	No. Strains	No. Studies	Range MICs	Geom Mean MIC_{50} (mg/L)	Geom Mean MIC_{90} (mg/L)	Distribution of Susceptibility, Minimum % Inhibited at Indicated Concentrations (mg/L) (+)								
						0.06	0.13	0.25	0.5	1	2	4	8	16
Gram Negative Aerobes														
Achromobacter xylosoxidans	64	3	1 - 8	2.67	4.79						21	63	100	
Acinetobacter calc. anitratus	183	8	0.007 - 12.5	0.21	0.39	4	6	55	90	96	97	97	97	100
Acinetobacter calc. alcaligenes	12	1	0.25 - 0.5	0.50	0.50				100					
Acinetobacter calc. haemolyticus	15	1	0.25 - 1	0.50	1.00				50	100				
Acinetobacter calcoaceticus	209	6	0.03 - 8	0.25	0.51			48	90	96	99	99	100	
Acinetobacter lwoffii	88	5	0.018 - 1	0.08	0.23	18	38	82	93	100				
Acinetobacter spp.	139	6	0.01 - >50	0.12	0.34		45	87	87	99	99	99	99	99
Aeromonas hydrophila	50	2	<0.05 - 4	0.21	0.79	5	10	55	55	91	91	100		
Alcaligenes denitrificans	9	2	0.25 - 4	1.00	1.85					78	78	100		
Alcaligenes faecalis	30	3	0.125 - 2	0.31	0.71			33	83	92	100			
Alcaligenes odorans	5	1	0.5 - 0.5	0.50	0.50				100					
Alcaligenes spp.	33	1	0.125 - 2	1.00	2.00					50	100			
Arizona hinshawii	5	1	<0.05 - 0.1	0.05	0.10	50	100							
Bordetella bronchicanis	18	2	0.125 - 32	2.24	4.00				14	14	14	93	93	93
Citrobacter diversus	173	8	0.1 - 2	0.35	0.64		7	37	74	79	100			
Citrobacter freundil	181	5	0.06 - 4	0.30	0.67		21	38	60	78	98	100		
Commamonas terrigena	4	1	<0.06 - 0.25	0.13	0.25		50	100						
Enterobacter aerogenes	136	6	0.05 - 8	0.29	0.93	6	19	32	56	69	91	98	100	
Enterobacter agglomerans	75	2	<0.13 - 4	0.46	0.92			5	54	90	90	100		
Enterobacter cloacae	306	6	0.03 - 12.5	0.21	1.07		34	36	47	80	98	99	99	100
Enterobacter spp.	824	13	0.03 - 8	0.34	1.18			32	47	77	90	99	100	
Escherichia coli	958	18	<0.06 - 25	0.11	0.24	19	54	75	92	97	98	98	99	99
Flavobacterium llb	33	3	0.15 - 128	2.97	28.07							50	50	50
Flavobacterium meningosepticum	14	2	16 - 64	21.53	43.07									29
Flavobacterium multivorum	6	1	0.5 - 32	8.00	32.00								50	50
Flavobacterium odoratum	6	1	2 - 8	2.00	8.00						50	50	100	
Haemophilus influenzae	341	11	0.01 - 32	0.97	1.88	2	4	7	27	45	77	80	94	99
Hafnia alvei	14	2	0.1 - 1	0.18	0.46		18	50	90	100				
Klebsiella oxytoca	31	2	0.1 - 0.5	0.19	0.37	7	23	70	100					
Klebsiella pneumoniae	499	11	0.01 - 4	0.16	0.38	4	31	69	89	93	98	100		
Klebsiella spp.	376	9	<0.06 - 4	0.20	0.33		22	71	89	97	97	100		
Moraxella osloensis	9	1	0.018 - 1.25	0.02	1.25	50	50	50	50	50	100			
Moraxella spp.	28	1	0.125 - 16	0.06	0.25	50	50	90	90	90	90	90	90	100
Moraxella urethralis	5	1	<0.13 - <0.13	<0.13	<0.13		100							
Morganella morganil	426	16	0.05 - 16	1.58	2.94				9	20	57	90	99	100

(+) Cumulative susceptibility distributions were tabulated by assigning for each study 50% of the number tested to the MIC_{50}, 40% to the MIC_{90} and 10% to the upper range cited and then taking the sum within each concentration range. Susceptibility was determined by both broth and agar dilution methods using an inoculum of 10^5 colony forming units (CFU) per mL.

TABLE 3 (continued)

THE *IN VITRO* ACTIVITY OF IMIPENEM AGAINST CLINICAL ISOLATES OF VARIOUS GRAM-POSITIVE AND GRAM-NEGATIVE AEROBIC AND ANAEROBIC SPECIES

Organism	No. Strains	No. Studies	Range MICs	Geom Mean MIC_{50} (mg/L)	Geom Mean MIC_{90} (mg/L)	Distribution of Susceptibility, Minimum % Inhibited at Indicated Concentrations (mg/L) (+)								
						0.06	0.13	0.25	0.5	1	2	4	8	16
Gram Negative Aerobes (cont'd)														
Neisseria gonorrhoeae	379	8	<0.004 - 1.28	0.09	0.28	18	41	75	83	97	100			
Neisseria gonorrhoeae (lact+)	23	1	<0.008 - 2	0.06	0.25	50	50	90	90	90	100			
Neisseria meningitidis	275	5	0.005 - >0.25	0.05	0.10	40	77	96	96	96	96	96	96	96
Pasteurella multocida	10	1	<0.06 - 2	0.50	1.00				50	90	100			
Plesiomonas shigelloides	15	1	<0.13 - 0.25	0.06	0.25		50	100						
Proteus mirabilis	581	15	0.03 - 32	1.12	2.90			10	13	29	62	89	99	99
Proteus vulgaris	158	8	0.05 - 8	0.92	2.96			12	17	29	64	90	100	
Proteus spp.	65	3	0.5 - 4	1.86	3.72					12	41	82	100	
Proteus/Providencia spp.	315	2	0.12 - 8	2.00	4.00						50	90	100	
Providencia rettgeri	88	5	0.05 - 8	0.64	1.47				37	70	86	93	100	
Providencia stuartii	131	7	<0.06 - 8	1.04	2.18			1	19	38	75	97	100	
Providencia spp.	87	5	0.12 - 8	1.19	1.80					41	93	96	100	
Pseudomonas VE:[VE-1;VE-2]	6	1	<0.13 - 0.5	0.06	0.50		50	50	100					
Pseudomonas acidovorans	39	3	0.075 - 2	0.41	0.89				44	81	100			
Pseudomonas aeruginosa	1917	32	0.05 - 250	1.42	3.25					27	64	85	93	99
Pseudomonas cepacia	77	6	0.018 - >50	13.84	26.46							10	30	68
Pseudomonas fluorescens	20	2	<0.13 - 16	2.00	11.31						50	50	75	100
Pseudomonas maltophilia	191	10	0.08 - >128	117.00	133.00									0
Pseudomonas pseudomallei	4	1	0.5 - 64	2.00	64.00						50	50	50	50
Pseudomonas putida	47	5	0.15 - 2	0.92	1.39				6	57	100			
Pseudomonas putrefaciens	20	2	0.5 - 5	1.41	4.73						50	63	100	
Pseudomonas stutzeri	53	3	0.15 - 2	0.61	0.88			5	45	66	100			
Pseudomonas alc.-P. Pseudoalcaligenes	16	2	<0.13 - 2	0.15	0.77		34	34	62	84	100			
Pseudomonas picketii [VA-1]	11	1	0.5 - 4	2.00	2.00						90	100		
Pseudomonas spp.	91	4	0.05 - 64	0.71	2.18				26	66	81	81	89	96
Rhodococcus spp.	11	1	<0.39 - <0.39	<0.39	<0.39				100					
Salmonella spp.	50	3	0.06 - 2	0.13	0.28		55	85	85	85	100			
Salmonella/Citrobacter spp.	10	1	<0.13 - 0.5	0.50	0.50				100					
Serratia marcescens	880	23	0.016 - 25	0.60	1.37		1	15	31	74	83	96	99	99
Shigella	33	2	0.1 - 1	0.17	0.27		33	67	97	100				
Yersinia like	13	1	<0.12 - 0.25	0.25	0.25			100						
Yersinia enterocolitica	198	4	0.06 - 1	0.24	0.48	2	4	52	97	100				
Yersinia pseudotuberculosis	15	1	<0.12 - 0.25	0.06	0.25	50	50	100						

(+) Cumulative susceptibility distributions were tabulated by assigning for each study 50% of the number tested to the MIC_{50}, 40% to the MIC_{90} and 10% to the upper range cited and then taking the sum within each concentration range. Susceptibility was determined by both broth and agar dilution methods using an inoculum of 10^5 colony forming units (CFU) per mL.

TABLE 3 (continued)

THE *IN VITRO* ACTIVITY OF IMIPENEM AGAINST CLINICAL ISOLATES OF VARIOUS GRAM-POSITIVE AND GRAM-NEGATIVE AEROBIC AND ANAEROBIC SPECIES

Organism	No. Strains	No. Studies	Range MICs	Geom Mean MIC_{50} (mg/L)	Geom Mean MIC_{90} (mg/L)	Distribution of Susceptibility, Minimum % Inhibited at Indicated Concentrations (mg/L) (+)								
						0.06	0.13	0.25	0.5	1	2	4	8	16
Gram Positive Aerobes														
Erysipelothrix rhusiopathiae	2	1	<0.015	<0.015	<0.015	100								
Listeria monocytogenes	43	4	<0.025 - 0.25	0.09	0.12	16	53	100						
Nocardia asteroides	74	4	<0.06 - 128	0.84	2.05			7	7	39	77	95	98	98
Staphylococcus aureus	855	20	0.008 - 8	0.03	0.07	73	80	87	93	99	99	99	100	
Staphylococcus aureus [Pen sen]	42	4	0.016 - 0.12	0.03	0.05	97	100							
Staphylococcus aureus [Pen res]	79	5	0.03 - 0.2	0.03	0.08	74	84	100						
Staphylococcus aureus [Meth res]	140	8	0.01 - 100	0.59	7.84	9	19	23	31	35	57	61	74	81
Staphylococcus epidermidis	509	16	0.008 - >64.0	0.08	1.59	29	36	49	56	61	81	88	89	90
Staphylococcus epidermidis [Pen res]	10	1	0.03 - 0.06	0.01	0.05	100								
Streptococcus (Beta Grp. B)	265	8	0.005 - 0.6	0.02	0.03	97	100							
Streptococcus (Grp. C)	8	1	<0.015	<0.015	<0.015	100								
Streptococcus (Grp. G)	10	1	<0.015	<0.015	<0.015	100								
Streptococcus agalactiae	115	5	0.012 - 0.1	0.02	0.04	93	100							
Streptococcus bovis	20	1	<0.015 - 0.1	0.02	0.10	50	100							
Streptococcus faecalis	778	22	0.016 - 128	0.94	1.69				16	52	87	91	97	98
Streptococcus faecium	22	2	2 - 64	23.35	46.70									23
Streptococcus pneumoniae [Pen res]	30	2	0.01 - 1	0.40	1.00			17	50	100				
Streptococcus pneumoniae	283	14	0.003 - 1.25	0.01	0.03	86	90	95	97	98	100			
Streptococcus pyogenes	304	10	0.0025 - 0.1	0.01	0.02	95	100							
Streptococcus spp.	194	5	0.002 - 2	0.02	0.03	81	87	87	94	94	100			
Viridans strep.	60	4	<0.001 - 4	0.01	0.05	71	78	96	96	96	96	100		
Viridans strep. [Pen res]	16	1	0.06 - 2	0.50	2.00				50	50	100			

(+) Cumulative susceptibility distributions were tabulated by assigning for each study 50% of the number tested to the MIC_{50}, 40% to the MIC_{90} and 10% to the upper range cited and then taking the sum within each concentration range. Susceptibility was determined by both broth and agar dilution methods using an inoculum of 10^5 colony forming units (CFU) per mL.

TABLE 3 (continued)

THE *IN VITRO* ACTIVITY OF IMIPENEM AGAINST CLINICAL ISOLATES OF VARIOUS GRAM-POSITIVE AND GRAM-NEGATIVE AEROBIC AND ANAEROBIC SPECIES

Organism	No. Strains	No. Studies	Range MICs	Geom Mean MIC_{50} (mg/L)	Geom Mean MIC_{90} (mg/L)	Distribution of Susceptibility, Minimum % Inhibited at Indicated Concentrations (mg/L) (+)								
						0.06	0.13	0.25	0.5	1	2	4	8	16
Gram Negative Anaerobes														
Bacteroides fragilis	745	14	<0.004 - 8	0.08	0.31	29	43	75	90	98	99	100		
Bacteroides distasonis	39	3	0.008 - 1	0.13	0.26	23	42	73	97	100				
Bacteroides fragilis spp.	74	3	0.03 - 2	0.05	0.33	42	42	66	92	96	100			
Bacteroides melanin. intermedius	47	3	<0.004 - 0.25	0.02	0.07	85	98	100						
Bacteroides ovatus	11	1	0.063 - 0.25	0.06	0.25	50	50	100						
Bacteroides thetaiotaomicron	109	5	0.008 - 2	0.15	0.41	11	32	61	95	97	100			
Bacteroides uniformis	10	1	0.016 - 0.25	0.13	0.25		50	100						
Bacteroides vulgatus	25	2	0.016 - 0.5	0.06	0.29	50	70	70	100					
Bacteroides spp.	279	7	<0.004 - 8	0.09	0.57	41	42	44	73	91	99	99	100	
Campylobacter fetus jejuni	88	2	0.01 - 0.125	0.05	0.07	76	100							
Eikenella corrodens	56	2	0.1 - 0.25	0.15	0.22		25	100						
Fusobacterium nucleatum	108	5	<0.004 - >256	0.04	1.21	50	50	56	89	93	93	93	93	93
Veillonella parvula	56	4	0.015 - 4	0.13	0.50	32	33	49	75	77	95	100		
Gram Positive Anaerobes														
Actinomyces spp.	8	2	<0.03 - 0.125	0.036	0.089	69	100							
Clostridium bifermentans	21	1	0.031 - 1	0.250	1.000			50	50	100				
Clostridium botulinum	16	1	<0.016 - 0.25	0.063	0.125	50	90	100						
Clostridium difficile	88	4	0.5 - 16	3.201	4.760						44	57	82	100
Clostridium perfringens	61	5	0.008 - 4	0.170	1.055	37	47	47	47	67	67	100		
Clostridium spp.	184	9	<0.004 - >16	0.115	0.590	34	45	57	78	89	90	90	97	99
Eubacterium spp.	4	1	0.06 - 0.5	0.125	0.500		50	50	100					
Gardnerella vaginalis	25	1	0.12 - 0.5	0.250	0.250			90	100					
Peptococcus asaccharolyticus	31	1	<0.008 - <0.01	0.004	0.008	100								
Peptococcus magnus	26	2	<0.008 - 0.063	0.025	0.050	100								
Peptococcus prevotii	25	1	<0.008 - 0.03	0.004	0.015	100								
Peptococcus/Peptostreptococcus spp.	230	5	<0.004 - 2	0.030	0.093	66	89	90	95	97	100			
Propionibacterium acnes	112	3	0.004 - 0.06	0.009	0.016	100								

(+) Cumulative susceptibility distributions were tabulated by assigning for each study 50% of the number tested to the MIC_{50}, 40% to the MIC_{90} and 10% to the upper range cited and then taking the sum within each concentration range. Susceptibility was determined by both broth and agar dilution methods using an inoculum of 10^5 colony forming units (CFU) per mL.

In addition to the species found partially or fully insensitive to imipenem, as listed in Table 3 (e.g., *P. maltophilia*, *P. cepacia*, Methicillin-resistant *S. aureus* and *S. epidermidis*, *S. faecium* and *Flavobacterium* spp.), other species generally reported insensitive to imipenem include *Corynebacterium* (J.K.), *Fusobacterium varium*, and species of *Mycobacterium* and *Chlamydia*.

The ratios of MBC to MIC in broth (inoculum of 10^5 CFU/mL) are shown in Table 4.

TABLE 4
RATIOS OF MBC TO MIC IN BROTH (INOCULUM OF 10^5 CFU/mL)

Organism	Strain Number	Imipenem		
		MIC	MBC	MBC:MIC
		mg/L		
Escherichia coli	2891	0.2	0.4	2
Enterobacter cloacae	2646	0.4	0.8	2
Klebsiella pneumoniae	2888	0.8	0.8	1
Proteus morganii	2833	1.6	3.1	2
Serratia marcescens	3548	1.6	1.6	1
Pseudomonas aeruginosa	40	0.8	0.8	1
Pseudomonas aeruginosa	3286	3.1	3.1	1
Staphylococcus aureus	2985	0.012	0.025	2
Susceptibility Distribution with Multiple Isolates	**No.**	**MIC_{90}**	**MBC_{90}**	**MBC_{90}:MIC_{90}**
		mg/L		
Pseudomonas aeruginosa	*40*	*8*	*8*	*1*
Bacteroides fragilis	*25*	*0.25*	*0.25*	*1*
Bacteroides thetaiotaomicron	*9*	*0.5*	*0.5*	*1*

Both the MICs and MBCs are little affected when susceptibilities are conducted in broth adjusted in pH over the range 7.0 to 7.4 or in broth supplemented with either 25 or 75 volume percent human serum. Increasing the inoculum from 10^3 to 10^7 CFU/mL generally has little effect on the observed MICs and bactericidal action of imipenem. An occasional MIC increase of 8- to 16-fold has been observed for some strains when the inoculum size was increased to 10^7 CFU/mL.

Resistance Studies

In general, imipenem is active against a wide range of species that exhibit resistance to one or more classes of beta-lactams by virtue of plasmid-mediated penicillinases or the mutational overproduction of chromosomally encoded cephalosporinases. This wide range of antibacterial activity of imipenem is in part attributable to the uniformly low rate of hydrolysis of imipenem by beta-lactamases of both plasmid and chromosomal origin (Table 5). In addition, imipenem has been shown to have an unusually rapid rate of diffusion relative to other classes of beta-lactam antibiotics across the outer membrane of the *Enterobacteriaceae* via channels in porin proteins. This higher diffusion rate has been correlated with the lower molecular weight of imipenem and with its zwitterionic structure. Imipenem generally is also active against isolates of *Pseudomonas aeruginosa* that have developed non-lactamase mediated resistance to the other classes of beta-lactams.

Rates of hydrolysis of imipenem relative to those of cephaloridine by various beta-lactamases are shown in Table 5.

TABLE 5

RATES OF HYDROLYSIS OF IMIPENEM RELATIVE TO THOSE OF CEPHALORIDINE BY VARIOUS BETA-LACTAMASES

Beta-Lactamase[a]	Richmond-Sykes Type	Source Organism	Rate of Hydrolysis of imipenem[b]
TEM-1	III	*Escherichia coli*	<1
TEM-2	III	*Escherichia coli*	<1
Oxa-1	V	*Escherichia coli*	<1
Oxa-2	V	*Escherichia coli*	<1
Oxa-3	V	*Escherichia coli*	<1
SHV-1	III	*Klebsiella*	<1
PSE-1	V	*Pseudomonas aeruginosa*	<1
PSE-2	V	*Pseudomonas*	<1
PSE-3	V	*Pseudomonas*	<1
PSE-4	V	*Pseudomonas*	<1
P99	Ia	*Enterobacter cloacae*	<1
	Ia	*Morganella morganii*	<1
	Ia	*Citrobacter freundii*	<1
		Bacilllus cereus	<1
	VI	*Bacteroides fragilis*	<1
		Staphylococcus aureus	<1
SAB-Abr.[c]	Id	*Pseudomonas aeruginosa*	<1
K1	IV	*Klebsiella oxytoca*	<1
	Ic	*Proteus vulgaris*	<1

[a] Classification of beta-lactamases was according to published methods.
[b] Relative rates based on a value of 100 for cephaloridine.
[c] Sabath-Abraham enzyme.

Among the *Enterobacteriaceae* species with inducible Type-I cephalosporinase, (e.g. *Citrobacter, Enterobacter, Morganella* and *Serratia*), imipenem-resistant mutants were not isolated using procedures that allowed the selection by cephalosporin antibiotics of mutants exhibiting resistance to multiple classes of beta-lactam antibiotics. In the case of *P. aeruginosa*, mutants exhibiting step-wise resistance to imipenem (4-16-fold multiple over the original MIC) are selected at frequencies (10^{-5} to 10^{-7}) comparable to those found with other beta-lactams. These mutants, as well as those reported to develop resistance during treatment with imipenem, retain their susceptibility to other classes of beta-lactam antibiotics as well as to the aminoglycosides. Imipenem-resistant mutants of *P. aeruginosa* do not exhibit elevated levels of beta-lactamases or altered penicillin binding proteins. Instead, loss of a transport pathway used exclusively by imipenem has been proposed as the resistance mechanism for these

mutants, which may in part explain their observed lack of cross-resistance with other beta-lactam antibiotics.

Antagonism by imipenem of the activity of other beta-lactam antibiotics has been observed, *in vitro*, when tested against species of *Enterobacteriaceae* and *Pseudomonas aeruginosa* that contain Type-I chromosomal encoded cephalosporinase. The antagonism results from the reversible induction of the cephalosporinase by subinhibitory levels of imipenem. The organisms with induced levels of cephalosporinase, however, remain susceptible to imipenem.

Synergistic interaction with other antibiotics such as amino-glycosides has been observed in gram-negative species including *P. aeruginosa* and gram-positive species such as *S. faecalis and Nocardia asteroides*.

Susceptibility Testing

Susceptibility testing of PRIMAXIN® is conducted with imipenem alone, since cilastatin is devoid of antimicrobial activity. Imipenem has been shown by *in vitro* tests to be active against certain strains found resistant when other beta-lactam discs are used. It is therefore recommended that the disc containing 10 µg of imipenem be used when conducting susceptibility tests. Alternatively, imipenem should be used for dilution susceptibility (broth and agar) tests. Susceptibility or resistance to imipenem are interpreted according to the following criteria, Table 6.

TABLE 6

INTERPRETATION OF SUSCEPTIBILITY CRITERIA OF IMIPENEM

	Zone Diameter[a] (mm)	Approximate MIC correlation (mg/L)[b]
Susceptible (susceptible to the usual doses)	≥ 16	≤ 4
Moderately Susceptible (intermediate)	14-15	8
Resistant	≤ 13	≥ 16

[a] Zone diameters are determined according to the Kirby-Bauer method as modified by the National Committee for Clinical Laboratory Standards [NCCLS], documented in M2-A3.

[b] MICs are determined by broth dilution method as recommended by the NCCLS, documented in M7-A.

PHARMACOLOGY

Animal pharmacology

Central Nervous System

Imipenem

In female mice (5 per dose level) imipenem at doses of 6, 30 and 150 mg/kg, I.P. showed no effect on behavior or in various pharmacological tests of central nervous system activity.

In male rats (11 per dose level) imipenem at doses up to 100 mg/kg, I.V. showed no effect on spontaneous locomotor activity and had no effect on the neuromuscular junction.

No behavioral or overt signs of central nervous system activity were observed when imipenem was given to squirrel monkeys at cumulative oral doses of 1, 3 and 9 mg/kg given at 90 minute intervals (0, 90 and 180 minutes) in an avoidance response test.

The effects of imipenem on the electrocardiogram (ECG), spontaneous electroencephalogram (EEG) and the EEG arousal response in rabbits immobilized by gallamine were studied. ECG and EEG were recorded for 60 minutes following drug administration. A single dose of 50 mg/kg, I.V. of imipenem (5 animals) had no effect on either the ECG or EEG. A single I.V. dose of 200 mg/kg, (6 animals) increased the threshold voltage for EEG arousal response significantly (22.9 ± 9.5%) only at 45 minutes.

Cilastatin Sodium

Cilastatin sodium was studied in mice in the same pharmacological tests of CNS activity as used for imipenem at doses of 6, 30 and 150 mg/kg, I.P. With the exception of a possible antagonism of neurotensin hypothermia in 2 out of 5 mice given 30 mg/kg, I.P., no effects were observed.

In rats at doses up to 100 mg/kg, I.V. cilastatin sodium showed no effect on spontaneous locomotor activity and had no effect on the neuromuscular junction.

In squirrel monkeys trained on a continuous avoidance schedule, avoidance response was unaltered by cilastatin sodium at cumulative oral doses of 5, 10 and 20 mg/kg administered at 90 minute intervals (0, 90 and 180 minutes).

Imipenem/Cilastatin Sodium

Imipenem/cilastatin sodium at doses of 25/25 and 100/100 mg/kg, I.V. induced no significant effect on central or autonomic nervous system activities in conscious mice.

The anticonvulsant activity of imipenem/cilastatin sodium was evaluated in mice on convulsions induced by electroshock, strychnine or pentylenetetrazol. At doses up to 100/100 mg/kg, I.V. no anticonvulsant effect was observed.

Imipenem/cilastatin sodium at doses up to 100/100 mg/kg, I.V. had no effect on spontaneous locomotor activity in rats. Imipenem/cilastatin sodium at doses up to 100/100 mg/kg, I.V. had no effect on the neuromuscular junction in rats (as

measured by the contractile response of the gastrocnemius muscle to electrical stimulation of the peroneal nerve).

Imipenem alone, cilastatin sodium alone and the combination (1:1 ratio) were administered intravenously to male rabbits at dosage levels of 50, 100 and 200 mg/kg to study the effect on the spontaneous electroencephalogram (EEG). Cefazolin was administered as a comparative agent at doses of 200, 400 or 1000 mg/kg. At 200 mg/kg imipenem alone caused seizure discharge in 1 of 11 rabbits 27 minutes after drug administration. This seizure discharge did not continue, but appeared again at 45 and 61 minutes. No effect on the spontaneous EEG activity was observed in the remaining 10 animals receiving 200 mg/kg of imipenem. Cilastatin had no effect on the EEG. Among rabbits receiving imipenem/cilastatin sodium at 200/200 mg/kg (the highest dose given), seizure discharge was observed in 2 of 11 rabbits from 15 minutes to 58 minutes after drug administration. Seizure discharge was observed with cefazolin at a dosage level of 400 mg/kg in 2 of 5 rabbits from 13 to 60 minutes after injection. Electrical disturbance of EEG activity was observed in all rabbits receiving cefazolin at 1000 mg/kg.

When tested in rat hippocampal slices *in vitro*, the GABA receptor blocking activity of imipenem was comparable to that seen with cefazolin. The GABA receptor blocking activity of imipenem/cilastatin sodium was somewhat less than that of imipenem alone. Cilastatin sodium alone had some antagonistic effect although it was significantly less than that observed with imipenem and other reference beta-lactam antibiotics.

In vivo studies in rats have shown that imipenem is convulsive after direct application of the drug into the cisterna magna. Coadministration of cilastatin sodium and imipenem in this model showed no differences in the convulsant potential compared to imipenem alone. Although direct introduction of imipenem into the rat brain is capable of producing convulsant activity, no evidence of such activity was observed in rats receiving imipenem alone at dosage levels up to 180 mg/kg/day S.C., once daily, for 6 months or with imipenem/cilastatin sodium

at dosage levels up to 320/320 mg/kg/day S.C., once daily, for 6 months. In addition, no evidence of convulsant activity was observed in rhesus monkeys receiving imipenem alone, at doses up to 180 mg/kg/day I.V., once daily, for 5 weeks or imipenem/cilastatin sodium at dosage levels up to 180/180 mg/kg/day S.C., once daily, for 6 months.

Imipenem, cilastatin sodium, and the 1:1 combination were evaluated in male rabbits at dosage levels of 50 and 100 mg/kg, I.V. for their effect on the EEG arousal response. At a dosage level of 200 mg/kg, imipenem alone increased the threshold voltage by approximately 23% at 45 minutes after drug administration. Cilastatin sodium at 50 mg/kg produced a slight but statistically significant decrease in the threshold voltage for EEG arousal response. A similar slight decrease in threshold voltage was noted for the combination at a dose of 200/200 mg/kg. The reference compound for this study (diazepam, 5 mg/kg) increased the threshold voltage by 87% at 15 minutes and by 70% at 60 minutes.

Cardiovascular and Respiratory System

Imipenem

Imipenem did not significantly lower blood pressure at 20 mg/kg, I.P. in spontaneously hypertensive rats, although a slight transient increase (11%) in mean arterial blood pressure was observed two hours after treatment.

In groups of 3 dogs anesthetized with sodium pentobarbital, imipenem given intravenously at doses of 25 mg/kg and 100 mg/kg had no effect on heart rate, arterial blood pressure, respiratory rate or ECG. In one dog (dosed at 100 mg/kg) heart rate increased by about 25 beats/min (21%) and systolic blood pressure increased about 16 mmHg (12%). In respiratory studies in dogs anesthetized with thiopental, imipenem at doses of 2.5 and 10 mg/kg, I.V. had no effect on the respiratory parameters measured (total lung resistance, dynamic lung compliance, tidal volume and respiratory rate).

Cilastatin Sodium

No appreciable change in basal blood pressure or heart rate was observed in spontaneously hypertensive rats or dogs dosed with cilastatin sodium at 10 mg/kg, I.V.

Cilastatin sodium at doses up to 100 mg/kg, I.V. did not change blood pressure, heart rate, respiratory rate and ECG in dogs anesthetized with sodium pentobarbital.

Imipenem/cilastatin sodium

At doses of 25/25 and 100/100 mg/kg, I.V. imipenem/cilastatin sodium significantly ($p < 0.05$) inhibited the carotid sinus reflexes (24.5% and 36% respectively) in dogs anesthetized with sodium pentobarbital.

In other studies in dogs anesthetized with sodium pentobarbital, a dose of imipenem/cilastatin sodium 100/100 mg/kg, I.V. decreased mean blood pressure (7 to 13 mmHg) within 4 to 15 minutes after the start of drug infusion, without any significant change in heart rate and respiration rate. This may have been related to the inhibition of the carotid sinus reflexes observed in the previous study. A dose of 25/25 mg/kg, I.V. did not affect these parameters.

Other Systems

Imipenem

In mice (male, 8 per dosage level), imipenem administered subcutaneously at doses of 2.5 to 20 mg/kg or intravenously at doses of 25 and 100 mg/kg had no effect on the intestinal propulsion rate.

No diuretic activity was observed in rats given imipenem at doses up to 10 mg/kg, I.P. or in dogs given 5 mg/kg, I.V.

In seven female dogs, gastric secretion evoked by gastrin tetrapeptide resulted in total acid output at the 0- to 30-minute collection which was significantly reduced

(59%, $p < 0.05$) following an oral dose of imipenem of 20 mg/kg. This was related to a reduction in output volume. The integrated 0- to 90-minute total acid output and output volume did not differ significantly ($p > 0.05$) from those in a placebo trial in the same animals. Acid concentration was not affected by imipenem. Basal gastric secretion in dogs was not affected following oral doses of 10 or 20 mg/kg of imipenem.

Cilastatin Sodium

In pylorus-ligated rats, cilastatin sodium (25 and 100 mg/kg, I.V.) showed no effect on basal gastric output, acid output, pH and pepsin output.

Cilastatin sodium (25 and 100 mg/kg, I.V.) showed no effect on intestinal propulsion in male mice.

Cilastatin sodium (10 mg/kg, I.V.) did not substantially change urinary Na^{+}, K^{+} or Ca^{++} excretion in beagle dogs.

In female dogs, cilastatin sodium (10 mg/kg, I.V.) did not significantly alter the response to gastrin tetrapeptide. Basal gastric output was reduced but not to a statistically significant degree.

Imipenem/cilastatin sodium

Imipenem/cilastatin sodium at doses of 25/25 and 100/100 mg/kg, I.V. had no effect on basal gastric secretion in pylorus-ligated rats. In mice, imipenem/cilastatin sodium (25/25 and 100/100 mg/kg, I.V.) had no effect on intestinal propulsion.

Metabolism and excretion

During the laboratory evaluation of imipenem as a single entity, low urinary recovery of the antibiotic was found in the mouse (26%), rabbit (51%), dog (8%), Rhesus monkey (41%) and the chimpanzee (13%), and this was subsequently confirmed in man. Metabolism was shown to occur primarily in the kidney,

affecting the secreted and filtered fraction of the antibiotic after its clearance from the blood.

The major pathway of metabolism of imipenem is by hydrolysis of the beta-lactam ring by the enzyme known as dehydropeptidase-I localized on the luminal (brush-border) surface of the proximal renal tubular epithelium. This enzyme has access to the antibiotic both in the glomerular filtrate and during the transcellular secretory process.

This low urinary tract bioavailability of imipenem is avoided by coadministration of cilastatin sodium, a potent inhibitor of dehydropeptidase-I.

The inhibition of dehydropeptidase-I by cilastatin sodium is competitive and freely reversible. Cilastatin sodium has been shown not to inhibit the activity of four other zinc metalloenzyme peptidases, including angiotensin converting enzyme. Cilastatin sodium is devoid of antimicrobial activity *per se*, and has no effect on the antimicrobial activity of imipenem.

HUMAN PHARMACOLOGY

Pharmacokinetics

PRIMAXIN® (imipenem and cilastatin sodium) was administered via intravenous infusion over 20 minutes at a single dose of 250/250 mg to 4 male subjects (mean age: 31.5 ± 0.6 years), at a single dose of 500/500 mg to 20 male subjects (mean age: 26.8 ± 4.1 years), and at a single dose of 1000/1000 mg to 8 male subjects (mean age: 24.8 ± 3.7 years). Peak plasma levels of imipenem and of cilastatin were measured at the end of a 20 minute infusion, and are presented in Table 7. Plasma levels of imipenem antimicrobial activity are proportional to the dose and decline to below 1 µg/mL or less in 4 to 6 hours.

TABLE 7
RANGE OF PEAK PLASMA LEVELS OF IMIPENEM AND CILASTATIN FOLLOWING A 20 MINUTE I.V. INFUSION OF PRIMAXIN®

	250/250 mg	500/500 mg	1000/1000 mg
Imipenem (µg/mL)	12 - 20	21 - 58	41 – 83
Cilastatin (µg/mL)	21 - 26	21 - 55	56 - 88

PRIMAXIN® was administered via the intravenous route, over a 30 minute period, every 6 hours, for a period of 10 days, at a dose of 1000/1000 mg, to a group of six male volunteers (mean age 28.2 ± 5.0).

Mean plasma and urine concentrations for imipenem are given in Figure 1 and Table 8 respectively.



FIGURE 1
MEAN IMIPENEM PLASMA CONCENTRATION PROFILES WHEN PRIMAXIN® IS ADMINISTERED AT A DOSE OF1000/1000 mg, BY I.V. INFUSION, OVER 30 min (every 6 h) (n = 6)

TABLE 8
MEAN IMIPENEM URINE CONCENTRATIONS (µg/mL ± S.D.) WHEN PRIMAXIN® IS ADMINISTERED AT A DOSE OF 1000/1000 mg BY I.V. INFUSION, OVER 30 min (every 6 h)

	0 - 2 h	2 - 4 h	4 - 6 h
Day 1	886.6 (±511.3)	562.8 (±269.3)	175.8 (±167.9)
Day 5	1026.1 (±503.9)	1185.8 (±932.4)	156.1 (± 93.77)
Day 10	1389.5 (±616.4)	891.5 (±430.6)	159.9 (± 49.1)

The pharmacokinetic parameters for imipenem and cilastatin, when PRIMAXIN® was administered at a dose of 1000/1000 mg, are summarized in Table 9.

TABLE 9
PHARMACOKINETIC PARAMETERS OF IMIPENEM AND CILASTATIN WHEN PRIMAXIN® IS ADMINISTERED AT A DOSE OF 1000/1000 MG BY I.V. INFUSION OVER 30 MIN (N = 6)

Time (days)	Volume of Distribution (L)	Area under the Plasma Concentration Time Curve Between 0 and 6 h (µg.h/mL)	Plasma Half-Lives (min)*	Dose Recovered in urine through 6 h (mg)	Cumulative Renal Clearance (mL/min)	Plasma Clearance (mL/min)
IMIPENEM						
Day 1	13.6 (±3.7)	73.3 (±10.4)	59.6	540.2 (±54.1)	126.5 (±29.9)	227.7 (±30.9)
Day 5	11.4 (±3.8)	74.5 (±10.9)	61.3	651.8 (±148.1)	139.9 (±27.4)	227.8 (±36.1)
Day 10	10.9 (±1.6)	79.7 (±7.1)	59.4	626.5 (±77.2)	131.3 (±21.0)	210.4 (±18.3)
CILASTATIN						
Day 1	10.3 (±3.9)	82.1 (±19.3)	57.5	698.6 (±33.9)	142.7 (±33.6)	208.9 (±43.0)
Day 5	9.5 (±1.4)	73.0 (±16.1)	50.7	ND	ND	236.5 (±44.9)
Day 10	9.7 (±2.1)	77.4 (±15.1)	50.8	ND	ND	221.6 (±38.6)

*Harmonic means

Excretion and metabolism

Imipenem, when administered alone, is metabolized in the kidneys by dehydropeptidase-I and therefore achieves relatively low levels in urine.

Cilastatin sodium is a specific inhibitor of this enzyme and it prevents renal metabolism of imipenem. When imipenem and cilastatin sodium are given concomitantly, approximately 70% of the administered imipenem and cilastatin sodium are recovered unchanged in the urine within 10 hours of administration, after which no further urinary excretion is detectable. Urine concentrations of imipenem in excess of 10 µg/mL can be maintained for up to 8 hours with PRIMAXIN®, at the 500 mg dose.

The remainder of the administered dose of imipenem is recovered in the urine as antibacterially inactive metabolites and fecal elimination of imipenem is essentially nil.

Approximately 10% of the cilastatin sodium administered is found as the N-acetyl metabolite, which has inhibitory activity against dehydropeptidase comparable to that of the parent drug. Activity of dehydropeptidase-I in the kidney returns to normal levels within approximately 8-12 hours after the elimination of cilastatin from the bloodstream.

No accumulation of imipenem and cilastatin in plasma is observed with regimens of PRIMAXIN® administered at therapeutic doses, in patients with normal renal function.

Serum Protein Binding

At serum concentration of 25 mg/L, the human serum protein binding of imipenem is 20%. Cilastatin sodium binding to protein was found to be approximately 35% in the human serum.

Tissue Concentrations

Concurrent imipenem concentrations in serum, tissues and body fluids are given in Table 10.

TABLE 10
IMIPENEM CONCENTRATIONS IN HUMAN TISSUES AFTER ADMINISTRATION BY I.V. INFUSION

Tissue/Fluid	Dose of Imipenem (mg)	Sampling time (min after dose)	No. of Specimens	Concentration: Tissue/Fluid (mg/L or mg/kg)	Concentration: Serum (mg/L)
				MEAN MAX (RANGE)	
Bile[1]	500	20	9	12.5 (5.25 - 20.3)	-
		180		>1 (0.46 - 2.73)	-
	1000	20	8	25.0 (10.7 - 51.28)	-
		180		(1.45 - 4.12)	-
				MEAN ± S.D.	MEAN ± S.D.(n=4)
Cerebrospinal[2]	1000	60	4	2.0 (±1.3)	22.3 (±14.6)
		90		1.5 (±0.1)	8.0 (± 1.6)
		120		2.7 (±2.3)	13.9 (±14.4)
				MEAN(RANGE)	MEAN PEAK±S.D.**
Saliva[3]	1000	15 - 60	10	0.38 (0.3 - 0.6)	34.9 (±4.0)
Sputum[3]	1000	15 - 120	7	4.4 (2.1 - 10.4)	(n=32)
Bone[3]	1000	30 - 120	10	2.6 (0.4 - 5.4)	
Wound Drainage[3]	1000	15 - 120	9	7.2 (1.7 - 22.6)	
Gastric Fluid[3]	1000	15 - 90	6	0.9 (0.4 - 1.7)	
				MEAN ± S.E.	MEAN ± S.E.
Heart Valves[4]	1000	0 - 60	3	3.3 (±0.7)	47.2 (±4.7)
Fat[4]	1000	0 - 60	10	0.8 (±0.3)	(n=16)
Muscle[4]	1000	0 - 60	10	2.5 (±0.7)	
Myometrium[4]	500	60 - 120	5	2.5 (±0.3)	14.6 (±1.6)
Endometrium[4]	500	60 - 120	5	1.6 (±0.3)	(n=5)
Salpinges[4]	500	60 - 120	2	1.4 (±0.1)	

** 15 min post infusion

(1) Mayer M, Tophoff C, Opperkuch W. Bile levels of imipenem following different dose regimens. Int J Clin Pharmacol Res 1985; V(5):325-9.

(2) Modal J, Vittecoq D, Decazes JM, Meulemans A. Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis. J Antimicrob Chemother 1985;16: 751-5.

(3) MacGregor RR, Gibson GA, Bland JA. Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment of serious infections. Antimicrob Agents Chemother 1986;29(2):188-92.

(4) Kümmel A, Schlosser V, Petersen E, Daschner FD. Pharmacokinetics of imipenem-cilastatin in serum and tissue. Eur J Clin Microbiol 1985;4(6):609-10.

Factors influencing pharmacokinetics

Age

Children

The pharmacokinetic results from two pediatric single dose studies are summarized in Table 11.

TABLE 11

MEAN VALUES OF PHARMACOKINETIC PARAMETERS OF IMIPENEM/CILASTATIN IN CHILDREN AFTER A SINGLE DOSE OF PRIMAXIN® (10/10 or 25/25 mg/kg) ADMINISTERED I.V. OVER 10-20 min

AGE RANGE (years)	No. PATIENTS	[AUC*] (µg.h/mL/mg)	PLASMA CLEARANCE (mL/min/kg)	VOLUME OF DISTRIBUTION (L/kg)	T½+ (min)	URINE RECOVERY (% OF DOSE)
2-12	20†	0.20 / 0.29 (n=9)/(n=3)	5.33 / 4.20 (n=9)/(n=3)	0.25 / 0.17 (n=9)/(n=3)	55.8 / 36.5 (n=20)/(n=10)	61.0 / 79.0 (n=7)/(n=5)
2- 9	9	0.18 / 0.20	5.40 / 4.90	0.22 / 0.15	53.7 / 37.9	41.0 / 66.0

* AUC expressed per milligram of drug administered.
\+ Harmonic means.
† Number of patients from which pharmacokinetic parameters were calculated are given in between parentheses.

The pharmacokinetic results from two pediatric studies in which PRIMAXIN® was administered in multiple doses are summarized in Table 12. PRIMAXIN® was administered at a dose of 25/25 mg/kg/q6 h for patients aged 3 months to <3 years and at a dose of 15/15 mg/kg/q6 h for patients aged 3 to 12 years.

TABLE 12
MEAN VALUES OF PHARMACOKINETIC PARAMETERS OF IMIPENEM/CILASTATIN IN CHILDREN AFTER MULTIPLE DOSES

TOTAL No. PTS	AGE RANGE (yrs)	TOTAL AUC[xx] (µg.h/mL/mg)**	PLASMA CLEARANCE (mL/min/kg)**	VOLUME OF DISTRIBUTION (L/kg)**	RENAL CLEARANCE (mL/min)	T ½+ (min)	DOSING INTERVAL UINARY RECOVERY (% OF DOSE)
106†	1 ≤ 3	0.18/[x] (n=1)/-	6.9/[x] (n=1)/-	0.23/[x] (n=1)/-	59/[x] (n=1)/-	67.9/[x] (n=1)/-	63.5/78.6 (n=1)/(n=1)
	3 ≤ 6	0.08/[x] (n=1)/-	12.7/[x] (n=1)/-	0.55/[x] (n=1)/-	85/[x] (n=1)/-	60.0/[x] (n=2)/-	39.4/61.7 (n=1)/(n=1)
	6 ≤ 9	0.10/[x] (n=1)/-	6.4/[x] (n=1)/-	0.33/[x] (n=1)/-	100/[x] (n=1)/-	54.7/[x] (n=1)/-	57.0/71.3 (n=1)/(n=1)
	9 ≤ 12	0.07/[x] (n=3)/-	6.0/[x] (n=3)/-	0.24/[x] (n=3)/-	118 to 161/[x] (n=3)/-	52.3/[x] (n=3)/-	53.0/65.6 (n=4)/(n=4)
178†	≤ 1	0.42/0.34 (n=10)/(n=3)	5.1/5.3 (n=10)/(n=3)	0.30/0.19 (n=10)/(n=3)	20 to 47/ 37 to 64 (n=6)/(n=3)	58.0/59.0 (n=10)/(n=3)	≥ 44/ ≥ 67[xxx] (n=6)/(n=5)
	1 ≤ 3	0.40/0.41 (n=10)/(n=3)	3.8/4.0 (n=6)/(n=3)	0.14/0.11 (n=6)/(n=3)	32 to 51/ 54 to 57 (n=5)/(n=2)	52.0/41.0 (n=6)/(n=3)	≥ 77/ ≥ 73[xxx] (n=5)/(n=4)
	3 ≤ 6	0.19/0.24 (n=7)/(n=2)	5.2/5.4 (n=7)/(n=2)	0.22/0.13 (n=7)/(n=1)	48 to 99/44 (n=6)/(n=1)	48.0/23.0 (n=7)/(n=2)	≥ 73/ ≥ 51[xxx] (n=6)/(n=5)
	6 ≤ 9	0.14/[x] (n=7)/-	4.7/[x] (n=7)/-	0.21/[x] (n=7)/-	53 to 116/[x] (n=4)/-	55.0/[x] (n=7)/-	≥ 63/ ≥ 89[xxx] (n=4)/(n=2)
	9 ≥ 12	0.17/0.22 (n=4)/(n=2)	4.4/4.4 (n=4)/(n=2)	0.22/0.13 (n=4)/(n=2)	28 to 124/ 37 to 87 (n=2)/(n=2)	73.0/39.0 (n=4)/(n=2)	≥ 75/ ≥ 64[xxx] (n=2)/(n=2)

** Geometric means
\+ Harmonic means
† Number of patients evaluated pharmacokinetically is indicated in parentheses
x Insufficient data
xx Dosing interval AUC (0-6h) expressed per mg of drug administered
xxx Means not provided

Representative plasma concentration profiles of imipenem and cilastatin at doses of 15/15 and 25/25 mg/kg are shown in Figure 2. In these studies, plasma concentrations of cilastatin were below detectable limits three hours postdosing. Steady state conditions for imipenem and cilastatin prevailed before the end of the fourth dose on Day 1.

Because of the short half-lives of imipenem and cilastatin, no accumulation was observed when PRIMAXIN® was given every 6 hours. As in the single dose pediatric studies, the disposition of imipenem and cilastatin resembled that of adults, except for a greater rate of cilastatin elimination.





FIGURE 2
Representative Mean Steady-State Plasma Concentrations of Imipenem and Cilastatin in Pediatric Patients Receiving Imipenem/Cilastatin Sodium Every Six Hours

Elderly

In 4 female and 2 male healthy volunteers, 65 to 75 years old (mean age 68.8) with normal renal function for their age, i.e., creatinine clearance 84.3 (±13.0) mL/min/1.73 m^2 (1.41(±0.2) mL/s/1.73 m^2), PRIMAXIN® was administered by intravenous infusion at a dose of 500/500 mg in 100 mL saline over a period of 20 minutes.

The pharmacokinetic parameters for imipenem and cilastatin are summarized in Table 13.

TABLE 13
PHARMACOKINETIC PARAMETERS FOR
IMIPENEM AND CILASTATIN IN THE ELDERLY
(SINGLE DOSE OF 500/500 mg BY I.V. INFUSION OVER 20 min)

	IMIPENEM		CILASTATIN	
PARAMETER	**MEAN (±S.D.)**	**RANGE**	**MEAN**	**RANGE**
Total urinary recovery (% dose)	58 ± 7	49 - 66	69 ± 11	49 - 80
Renal clearance (mL/min)	79 ± 11	67 - 95	98 ± 26	64 - 133
Plasma clearance (mL/min)	132 ± 10	122 - 147	142 ± 22	117 - 171
Total AUC (µg . h/mL)	64 ± 5	57 - 68	60 ± 9.1	49 - 71
Plasma half-life (min)	90[+]	84 - 102	66[+]	54 - 96

[+] Harmonic means

No dosage adjustment is necessary for elderly patients whose degree of renal function is normal for their age.

Impaired Renal Function

PRIMAXIN® was administered to six healthy male volunteers and 25 patients with different degrees of renal impairment at a dose of 250/250 mg, in single I.V. infusions over 5 minutes.

The pharmacokinetic parameters for imipenem and cilastatin are summarized in Table 14 and the plasma concentration profiles are shown in Figures 3 and 4 respectively.

TABLE 14

PHARMACOKINETIC PARAMETERS FOR IMIPENEM AND CILASTATIN IN PATIENTS WITH RENAL FAILURE

(SINGLE DOSE OF 250/250 mg BY I.V. INFUSION OVER 5 min)

GROUP No.	No. PTS	MEAN AGE (yrs)	CREATININE CLEARANCE mL/min/1.73 m^2 (mL/s/1.73 m^2)	% DOSE URINARY RECOVERY	RENAL CLEARANCE (mL/min	PLASMA CLEARANCE (mL/min)	[AUC]^{x} µg.h/mL	T1/2^{xx} (min)
			IMIPENEM					
I	6	22.8	>100 (>1.7)	46.2	101.9	219.5	19.8	56
II	6	41.8	31-99 (0.52-1.65)	51.0^{y}	77.7^{y}	157.2	30.3	92
III	9	50.8	10-30 (0.17-0.50)	26.1^{zz}	24.2^{zz}	86.2	51.6	139
IV	2	32&67	<10 (<0.17)	11.3	8.5	69.3	60.6	160
V_a	4	42.3	Hemodialysis†			184.0	23.1	74
V_b	4	61.5	Hemodialysis††	3.4	1.8	59.1	73.1	181
			CILASTATIN					
I	6	22.8	>100 (>1.7)	59.4	100.7	168.5	25.4	54
II	6	41.8	31-99 (0.52-1.65)	71.2y	71.3y	99.9	45.7	84
III	9	50.8	10-30 (0.17-0.50)	61.9z	23.9zz	38.4	135.3	198
IV	2	32&67	<10 (<0.17)	39.4	6.5	16.2	261.4	462
V_a	4	42.3	Hemodialysis†			74.9	56.7	132
V_b	4	61.5	Hemodialysis††	17.9	2.0	11.4	416.8	696

† Received dose during hemodialysis
†† Measurements done between dialysis sessions
x AUC normalised to a 250 mg dose
xx Harmonic means
y n = 5
z n = 6
zz n = 8



† Received dose during hemodialysis
†† Measurements done between dialysis sessions

FIGURE 3

MEAN IMIPENEM PLASMA CONCENTRATIONS FOLLOWING A SINGLE-DOSE OF PRIMAXIN® (250/250 mg I.V., OVER 5 min) TO SUBJECTS WITH VARYING DEGREES OF RENAL INSUFFICIENCY



FIGURE 4

MEAN CILASTATIN PLASMA CONCENTRATIONS FOLLOWING A SINGLE-DOSE OF PRIMAXIN® (250/250 mg I.V., OVER 5 min) TO SUBJECTS WITH VARYING DEGREES OF RENAL INSUFFICIENCY

PRIMAXIN® was administered to 15 hospitalized patients (age range: 39-72 years) with proven or suspected urinary infection, at a dose of 500/500 mg by I.V. infusion over 20 minutes, repeated every 6 hours, for 3 to 10 days.

The pharmacokinetic parameters for imipenem and cilastatin are summarized in Table 15.

Repeated administration did not alter the disposition of either imipenem or cilastatin from that observed after a single dose and steady state prevailed by the end of first day dosing.

TABLE 15

PHARMACOKINETIC PARAMETERS FOR IMIPENEM AND CILASTATIN WHEN PRIMAXIN® WAS ADMINISTERED AT 500/500 mg BY I.V. INFUSION OVER 20 min - EVERY 6 h

GROUP	DOSE	URINARY RECOVERY 0 - 6 h (mg)	PLASMA CLEARANCE RENAL CLEARANCE (mL/min)	PLASMA CLEARANCE (mL/min)	[AUC] 0 - 6 h (µg.h/mL)	T1/2[x] (min)
IMIPENEM						
I[a]	1st	250.1 (± 45.5) n = 9	105.1 (±39.0) n = 9	201.2 (±63.8) n = 9	42.9(±10.7) n = 9	80 n = 9
	N[th]	287.0 (±100.7) n = 8	128.3 (±69.1) n = 8	222.5 (±46.8) n = 8	39.1 (± 8.9) n = 8	72 n = 9
II[b]	1st	183.5 (± 39.8) n = 4	69.3 (±14.0) n = 4	167.0 (±50.9) n = 5	50.7(±16.8) n = 5	98 n = 5
	N[th]	231.5 (± 40.3) n = 4	87.8 (±26.2) n = 4	175.7 (±49.5) n = 5	51.0(±15.9) n = 5	100 n = 5
CILASTATIN						
I[a]	1st	342.1 (± 70.6) n = 3	122.5 (±22.7) n = 3	214.7 (±59.3) n = 9	40.9(±11.8) n = 9	57 n = 9
	N[th]	258.7 (± 73.6) n = 3	100.8 (±26.2) n = 3	222.6 (±60.2) n = 8	39.9(±10.9) n = 8	55 n = 9
II[b]	1st	204.6 n = 1	50.3 n = 1	148.6 (±60.4) n = 6	59.6(±23.9) n = 6	92 n = 6
	N[th]	224.9 (± 59.6) n = 2	71.8 (±26.6) n = 2	158.8 (±60.8) n = 6	60.7(±27.1) n = 6	86 n = 6

[a] Group I = glomerular filtration rate ≥ 100 mL/min/1.73 m^2 (1.667 mL/s/1.73 m^2) and N ≥ 16 doses.

[b] Group II = glomerular filtration rate ≤ 100 mL/min/1.73 m^2 (1.667 mL/s/1.73 m^2) but ≥ 50 mL/min/1.73 m^2 (0.834 mL/s/1.73 m^2) and N ≥ 15 doses.

[x] Harmonic means.

Six hospitalized patients (4 females, 2 males, mean age 52.3) with a glomerular filtration rate of less than 15 mL/min/1.73 m^2 (0.25 mL/s/1.73 m^2) but not requiring hemodialysis, were administered PRIMAXIN® at a dose of 500/500 mg by I.V. infusion over 20 minutes, every 12 hours for nine doses.

The pharmacokinetic parameter estimates are summarized in Table 16.

TABLE 16

PHARMACOKINETIC PARAMETER ESTIMATES IN PATIENTS WITH SEVERELY IMPAIRED RENAL FUNCTION

	DOSE No.	IMIPENEM MEAN	CILASTATIN MEAN
Urinary recovery	1	15.2	38.0
(% administered dose)	9	13.8	46.7[x]
		(1.2)	(6.5)
Renal clearance	1	7.8	10.4
(mL/min)	9	7.1[x]	9.1
		(0.6)	(1.6)
Plasma clearance	1	51	21
(mL/min)	9	54[xxx]	19
		(1.2)	(1.9)
12-hour AUC	1	158	313
(µg hr/mL)	9	159	431[xxx]
		(4.3)	(33)
Plasma half-life[a]	1	2.9	5.7
(h)	9	2.6[xx]	5.5

[x] Different from Dose 1, .05 < p. .10
[xx] Different from Dose 1, .01 < p. .05
[xxx] Different from Dose 1, p. .01
[a] Inverse (harmonic) transformed data
Numbers in parentheses are within patient standard deviations.

Probenecid

In twelve male volunteers (mean age 29.5, range 23-37) PRIMAXIN® was administered at a dose of 500/500 mg with and without probenecid (1 g orally at ten hours and one hour prior to treatment). The urinary recovery of imipenem and cilastatin and their pharmacokinetic data are given in Table 17.

TABLE 17
EFFECT OF PROBENECID ON THE PHARMACOKINETICS AND URINARY RECOVERY OF IMIPENEM AND CILASTATIN WHEN IMIPENEM/CILASTATIN SODIUM (500/500 mg) WAS ADMINISTERED

	IMIPENEM/ CILASTATIN SODIUM	IMIPENEM/CILASTATIN SODIUM PLUS PROBENECID
Imipenem		
Plasma clearance (mL/min)	185 (± 32)[x]	159 (± 24)
AUC (µg.h/mL)	46 (± 7)	53 (± 8)
Plasma half-life (min)[xx]	58	66
Urinary recovery (% dose)	66 (± 3)	55 (± 6)
Renal clearance (mL/min)	125 (± 20)	88 (± 17)
Cilastatin		
Plasma clearance (mL/min)	218 (± 39)	89 (± 10)
AUC (µg.h/mL)	39 (± 7)	95 (± 11)
Plasma half-life (min)[xx]	48	102
Urinary recovery (% dose)	75 (± 6)	75 (± 8)
Renal clearance (mL/min)	173 (± 31)	70 (± 9)

[x] Mean (±S.D.)

[xx] Harmonic means

TOXICOLOGY

Acute Toxicity

	LD_{50}	
	RAT	**MOUSE**
Imipenem I.V.	>2000 mg/kg	_1500 mg/kg
Cilastatin Sodium I.V.	_5000 mg/kg	_8709 mg/kg
PRIMAXIN® I.V.	_1000 mg/kg	_1100 mg/kg

Subacute and Chronic Toxicity

Imipenem

The principal studies used to evaluate the subacute and chronic toxicity of the product are shown in Table 18.

Animal studies showed that the toxicity produced by imipenem as a single entity, was limited to the kidney. Nephrotoxicity (characterized by proximal tubular necrosis) was observed in rabbits and monkeys receiving high doses of imipenem (150 mg/kg, I.V. and 180 mg/kg, I.V. respectively); the rabbit is more sensitive to the nephrotoxic effect of imipenem than is the monkey. No adverse effects were observed after 6 months of administration of imipenem in rats (25 males and 25 females per dosage level), at dosage levels up to 180 mg/kg/day, or in monkeys (5 males and 5 females per dosage level) at dosage levels up to 120 mg/kg/day.

TABLE 18

PRINCIPAL SUBACUTE AND CHRONIC TOXICITY STUDIES WITH PRIMAXIN®[1]

Duration	Species, Number/Sex/ Group	Dosage Levels (mg/kg/day)	No Adverse Effect Level (mg/kg/day)	Principal Effects Observed
Studies with Imipenem Alone				
5-Week, I.V.	Rat, 15	20, 60, 180	180	No adverse effects observed.
5-Week, I.V.	Monkey, 3M, 3F	20, 60, 180	60	1/6 dead with renal tubular necrosis at 180; an additional death from unknown cause at 180 presumed related to injection of highly concentrated drug solution necessitated by dosage level.
6-Month, I.V. (w/3-mo interim necropsy)	Rat, 25 (10 for interim necropsy)	20, 60, 180	180	Increased rate of weight gain in males at 60 and 180; no adverse effects seen.
6-Month, I.V. S.C. (w/3-mo interim necropsy)	Monkey, 5 (2 for interim necropsy)	30, 60 I.V. 120 S.C.	120	No adverse systemic effects seen.
Studies with Cilastatin Alone				
5-Week, I.V.	Rat, 15	20, 100, 500	500	No adverse effects seen.
5-Week, S.C	Rat, 15	500, 1250, 3125	500	Renal tubular vacuolation seen at 1250 and 3125.
5-Week, I.V.	Monkey, 3	20, 100, 500	500	No drug-induced adverse effects.
14-Week, I.V.	Rat, 15	20, 100, 500	500	No changes related to treatment.

[1] Although many studies in addition to those listed here were conducted, this list presents the principal studies which formed the basis of the safety evaluation of this drug.

TABLE 18
PRINCIPAL SUBACUTE AND CHRONIC TOXICITY STUDIES WITH PRIMAXIN® (continued)

Duration	Species, Number/Sex/ Group	Dosage Levels (mg/kg/day)	No Adverse Effect Level (mg/kg/day)	Principal Effects Observed
Studies with Imipenem and Cilastatin Sodium in Combination (PRIMAXIN®)				
5-Week, I.V., S.C.	Rat, 15	20/20, 80/80 I.V. 320/320 S.C.	320/320	No drug-induced adverse effects.
5-Week, I.V., S.C.	Monkey, 3	20/20, 60/60 I.V. 180/180 S.C.	180/180	No changes related to treatment.
14-Week, I.V., S.C.	Rat, 15	20/20, 80/80, 320/320	320/320	No changes related to treatment.
14-Week, S.C.	Infant Monkey, 3	20/20, 60/60 180/180	180/180	No adverse drug-induced changes.
10-Week, S.C.	Newborn Monkey, 5M, 3F	180/180	180/180	No drug-induced adverse effects.
6-Month, I.V., S.C.	Rat, 30	20/20, 80/80 I.V. 320/320 S.C.	320/320	No adverse effects observed.
6-Month, I.V., S.C.	Monkey, 4	20/20, 60/60 I.V. 180/180 S.C.	180/180	No adverse effects observed.

Cilastatin Sodium

No adverse effects were noted after intravenous administration of cilastatin sodium to rats (15 males and 15 females per dosage level) at doses up to 500 mg/kg for 14 weeks and monkeys (3 males and 3 females per dosage level) at doses up to 500 mg/kg for five weeks. In rats (15 males and 15 females per dosage level) given cilastatin sodium at dosages of 1250 or 3125 mg/kg/day, subcutaneously, very slight to slight proximal renal tubular degeneration was observed. After 5 weeks on these doses, no tubular necrosis was found, and there were no changes in any other tissues. Renal function remained normal.

Imipenem/Cilastatin Sodium

Co-administration of cilastatin sodium with imipenem in a 1:1 ratio prevented the nephrotoxic effects of imipenem in rabbits and monkeys, even when the dose of imipenem was 360 mg/kg or 180 mg/kg/day, respectively. These dosage levels are nephrotoxic when administered without cilastatin. This protective effect was seen in the monkey through 6 months of co-administration.

A series of studies performed in rabbits demonstrated that cilastatin sodium prevents the nephrotoxicity of imipenem in animals by preventing its entry into the tubular cells; this action is apparently distinct from the inhibition by administration of dehydropeptidase-I.

Reproduction studies

The principal studies performed to evaluate the effect of imipenem or cilastatin sodium alone or in combination on reproductive parameters or fetal development are shown in Table 19.

Fertility

The effect of imipenem/cilastatin sodium on fertility was assessed in male and female rats administered doses up to 320/320 mg/kg/day. Drug was administered to males for 12 weeks prior to mating and throughout the mating

period. Females received drug beginning 15 days prior to mating, during mating and through Day 19 of gestation.

The only effect of imipenem/cilastatin sodium in these studies was a very slight but statistically significant embryotoxicity and/or fetotoxicity. This was expressed as an increase in the resorption rate among animals receiving 80/80 and 320/320 mg/kg/day as well as a decrease in the number of live fetuses per pregnant female at 20/20 and 80/80 mg/kg/day. No decrease in the number of live fetuses per pregnant female was observed at the highest dosage level and the number of live pups per pregnant female on Day 1 postpartum in all dosage groups were comparable to the control group. The incidence of incompletely ossified sternebra was slightly increased in the 320/320 mg/kg/day group compared to the controls. Although these effects are subtle in nature and small in magnitude, they suggest a slight embryotoxic effect of imipenem/cilastatin sodium at high dosage levels in the rat.

TABLE 19

PRINCIPAL REPRODUCTIVE TOXICITY STUDIES WITH PRIMAXIN®[1]

Type of Study	Species, Number/Sex/Group	Dosage Levels (mg/kg/day)	Principal Effects Observed
Studies with Imipenem Alone			
Teratology, I.V.	Rat, 23	100, 300, 900	No evidence of fetal malformations; no effect postnatal growth and Behavior
Teratology, I.V.	Rabbit, 20	10, 30, 60	No teratogenic effect.
Studies with Cilastatin Sodium Alone			
Teratology, I.V./S.C.	Rat, 25	40, 200, 1000	No teratogenic effect.
Teratology, I.V./S.C.	Rabbit, 10	30, 100, 300	No teratogenic effect.
Studies with Imipenem and Cilastatin Sodium in Combination (PRIMAXIN®)			
Fertility, I.V./S.C.. (w/o post-weanling exam)	Rat: 15 male, 30 female	20/20, 80/80, 320/320	No evidence of adverse effect on fertility (slight decrease in live fetal weight at 320/320).
Teratology, I.V.	Mouse, 25	20/20, 80/80, 320/320	No teratogenic effect
Teratology, I.V./S.C. (with post-natal exam)	Rat, 35	20/20, 80/80, 320/320	No teratogenic effect, no adverse effect postnatal growth or behavior.
Late Gestation and Lactation I.V./S.C	Rat, 20	20/20, 80/80, 320/320	No adverse effects observed.
Teratology, I.V./S.C.	Cynomolgus Monkey, 11 (I.V.), 14 (S.C.)	I.V.: 40/40 S.C.: 160/160	Emesis, body weight loss, deaths, abortions at both dose levels; histologic examination of tissues showed no cause of death. No evidence of teratogenicity
Teratology by Infusion 45 (total)	Cynomolgus Monkey	100/100 (Days 21-30; 31-40; 41-50).	Drugs infused daily at 3 mg/mL for 10-day periods No apparent relationship between drug-induced toxicity (emesis) and embryotoxicity.

[1] Although several additional studies were performed to evaluate various aspects of reproduction, the studies presented form the basis of the safety evaluation of PRIMAXIN®.

Teratology

No evidence of a teratogenic effect was observed in rats or rabbits receiving imipenem or cilastatin sodium alone or in combination. Imipenem alone was evaluated at dosage levels up to 900 mg/kg/day, cilastatin sodium alone at dosage levels up to 1000 mg/kg/day and the two drugs in combination at dosage levels up to 320/320 mg/kg/day in rats.

The characteristic intolerance of rabbits to cephalosporin antibiotics was demonstrated in a teratology study with imipenem alone in this species at a dosage level up to 60 mg/kg/day. Maternotoxicity and feto- and embryotoxicity were observed at 60 mg/kg/day. The embryo- and fetotoxicity is considered to be secondary to the excess maternotoxicity observed in these studies. In the presence of these effects, there was still no evidence of teratogenicity. No evidence of a teratogenic effect was observed in rabbits receiving cilastatin sodium alone at doses up to 300 mg/kg/day.

Monkeys

In a range-finding study imipenem/cilastatin sodium was administered daily by bolus intravenous injection to non-pregnant cynomolgus monkeys for 30 days at doses of 20/20, 60/60, and 120/120 mg/kg/day (4 females per group) in order to establish dosage levels for subsequent studies. Four additional non-pregnant female monkeys were treated with 180/180 mg/kg/day subcutaneously for 30 days and a control group of 4 monkeys were treated intravenously with 0.9% sodium chloride. Emesis or diarrhea were seen on one or two occasions during treatment in some monkeys in the 60/60 and 120/120 mg/kg/day groups. Three animals in the 180/180 mg/kg/day subcutaneous group had occasional diarrhea during treatment.

In a teratology study, a bolus intravenous dose of 40/40 mg/kg/day and a subcutaneous dose of 160/160 mg/kg/day were administered to pregnant cynomolgus monkeys on Days 20 to 50 of gestation (11 and 14 monkeys per group, respectively). A control group of 14 pregnant monkeys were treated with 0.9% sodium chloride I.V. Both doses of imipenem/cilastatin sodium were

maternotoxic and resulted in deaths, reduced appetite, body weight loss, diarrhea, and emesis. In the 40/40 and 160/160 mg/kg/day groups, 7 of 11 and 5 of 14 monkeys lost their embryos. This is considered to reflect the obvious maternotoxicity evident at these dosage levels. There was no evidence of a teratogenic effect in surviving fetuses.

A study was conducted to determine the disposition and metabolism of imipenem/cilastatin sodium in pregnant and non-pregnant cynomolgus monkeys (4-5 monkeys per group). A bolus intravenous dose of 100/100 mg/kg/day was administered for 10 days and the first and last dose contained radioactive imipenem. The data suggest that metabolism or disposition is not directly responsible for the increased sensitivity of pregnant monkeys to imipenem/cilastatin sodium-induced toxicity.

In a teratology study in cynomolgus monkeys, imipenem/cilastatin sodium (100/100 mg/kg/day) was administered to 10 pregnant monkeys per group by slow infusion for 3 consecutive 10-day periods (Days 21-30; 31-40; 41-50). Three groups of 5 pregnant monkeys each were similarly treated with the vehicle. Pregnancy was confirmed by tests for macaque chorionic gonadotropin and the maintenance of pregnancy was assessed through periodic ultrasound examinations. Prior to parturition the fetuses were delivered by cesarean section and examined for malformations. Although there was no evidence of fetal external, visceral or skeletal malformations, there was an increase in the incidence of embryonic/fetal loss in the drug-treated monkeys (7 of 30, 23%) compared to the controls (0 of 15, 0%). Maternotoxicity (emesis and/or gagging during or after treatment) was observed in 4 of the 7 monkeys with embryonic/fetal loss.

Gestation and Postnatal Development

The effect of imipenem/cilastatin sodium during gestation and the postnatal period was studied in rats at doses up to 320/320 mg/kg/day. Imipenem/cilastatin sodium had no effect on growth or survival of offspring.

Genotoxicity

No evidence of drug-induced genetic toxicity was seen in the tests performed with imipenem or cilastatin sodium; these tests are listed in Table 20.

TABLE 20

PRINCIPAL GENETIC TOXICITY STUDIES WITH PRIMAXIN®

Type of Study	Species, Number/Sex/ Group	Dosage Levels (mg/kg/day)	Principal Effects Observed
Studies with Imipenem Alone			
Mutagenic	V-79 cells	3, 10, 20, 36 mM final concentration in medium	No evidence of mutagenic activity
Studies with Cilastatin Sodium Alone			
Mutagenic	Microbial Mutagenesis *(S. typhimurium)*	With and without S-9:** 30, 100, 300, 1000, 2,000 µg/plate	Negative
Studies with Imipenem and Cilastatin Sodium in Combination (PRIMAXIN®)			
Mutagenic	V-79 cells	With S-9: 1,3,4,5,7,9,11 mM Without S-9: 3,5,10,15 mM	No mutagenic activity detected
Mutagenic	Unscheduled DNA synthesis, Rat hepatocytes	3,10,14,22 mM final concentration in medium	No increase in labelled nuclei
Mutagenic	*In vivo* cytogenetic mouse bone marrow	59, 197, 590 mg/kg	No chromosomal aberration seen
Mutagenic	*In vitro* cytogenetic (range-finding)	With and without S-9: 0.2, 0.67, 2.0, 6.7, 20 mM and 2.0, 6.7, 20.0, 67 µM	Increased incidence of sister chromatid exchanges; study repeated and *in vitro* and *in vivo* sister chromatid exchange studies performed (below).
Mutagenic	*In vitro* chromosomal aberration assay	With S-9: 8.5, 6.4, 4.2, 2.1, 1.1 mM; Without S-9: 21.2 1.2 17.0, 12.7, 8.5, 4.2 mM	Negative

** Rat liver microsomal activation system

REFERENCES

1. Acar JF. Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience. Rev Infect Dis 1985;7(Suppl 3):S513-S517.

2. Barza M. Imipenem: first of a new class of beta-lactam antibiotics. Ann Intern Med 1985;103:552-60.

3. Calandra GB, Brown KR, Grad LC, Ahonkhai VI, Wang C, Aziz MA. Review of adverse experiences and tolerability in the first 2516 patients treated with imipenem/cilastatin. Am J Med 1985;78(Suppl 6A):65-70.

4. Calandra G, Ricci F, Wang C, Brown K. Cross-resistance and imipenem. Lancet 1986;340-1.

5. Eron LJ. Imipenem/cilastatin therapy in bacteremia. Am J Med 1985; 78(Suppl 6A):87-91.

6. Hashizume T, Ishino F, Nakagawa JI, Tamaki S, Matsuhashi M. Studies on the mechanism of action of imipenem (N-formimidoyl thienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli. J Antibiot 1984;XXXVII(4):394-400.

7. Iannini PB, Kunkel MJ, Hilton E, Iannini GM. Imipenem/cilastatin: general experience in a community hospital. Am J Med 1985;78(Suppl 6A):122- 6.

8. Ito K, Izumi K, Takagi H, Tamaya T, Hayasaki M. Fundamental and Clinical Evaluation of Imipenem/Cilastatin sodium in the Perinatal Period. Jpn J Antibiot 1988;41(11):1778-85.

9. Jones RN. Review of the in vitro spectrum of activity of imipenem. Am J Med 1985;78(Suppl 6A):22-32.

10. Kager L, Nord CE. Imipenem/cilastatin in the treatment of intraabdominal infections: a review of worldwide experience. Rev Infect Dis 1985; 7(Suppl 3):S518-S521.

11. Kirkpatrick B, Ashby J, Wise R. Beta-lactams and imipenem. Lancet 1986; 802.

12. Kropp H, Sundelof JG, Kahan JS, Kahan FM, Birnbaum J. MK0787 (N-formimidoyl thienamycin): evaluation of *in vitro* and *in vivo* activities. Antimicrob Agents Chemother 1980;17(6):993-1000.

13. Kropp H, Sundelof JG, Hajdu R, Kahan FM. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase: dehydropeptidase-I. Antimicrob Agents Chemother 1982;22:62-70.

14. Kropp H, Gerckens L, Sundelof JG, Kahan FM. Antibacterial activity of imipenem: the first thienamycin antibiotic. Rev Infect Dis 1985;7(Suppl 3):S389-S410.

15. Livermore D. Class I beta-lactamase expression in *Pseudomonas aeruginosa* and cephalosporin resistance. Lancet 1986;450.

16. Neu HC. Carbapenems: special properties contributing to their activity. Am J Med 1985;78(Suppl 6A):33-9.

17. Norrby SR. Imipenem/cilastatin: rationale for a fixed combination. Rev Infect Dis 1985;7(Suppl 3):S447-S451.

18. Norrby SR. Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Lancet 1984;1(8382):868-71.

19. Nord CE, Kager L, Philipson A, Stiernstedt G. Effect of imipenem/cilastatin on the colonic microflora. Rev Infect Dis 1985; 7(Suppl 3):S432-S434.

20. Pastel DA. Drug review: imipenem-cilastatin antibiotic combination. Clin Pharm 1986;5:719-36.

21. Rogers JD, Meisinger MAP, Ferber F, Calandra GB, Demetriades JL, Bland JA. Pharmacokinetics of imipenem and cilastatin in volunteers. Rev Infect Dis 1985;7(Suppl 3):S435-S446.

22. Salata RA, Gebhart RL, Palmer DL, Wade BH, Scheld WM, Groschel DHM, Wenzel RP, Mandell GL, Duma RJ. Pneumonia treated with imipenem/cilastatin. Am J Med 1985;78(Suppl 6A):104-9.

23. Solomkin JS, Fant WK, Rivera JO, Alexander JW. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med 1985;78(Suppl 6A):85-91.

24. Thabaut A, Philippon A, Meyran M. Activité comparée des b□ta-lactamines actives sur *Pseudomonas aeruginosa* en fonction des phénotypes de résistance. Presse Med 1984;768-71.

25. Wade JC, Standiford HC, Drusano GL, Johnson DE, Moody MR, Bustamante CI, Joshi JH, deJongh C, Schimpff SC. Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer. Am J Med 1985;78(Suppl 6A):62-72.